首页> The Lancet. Global health> Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kwabena,Asare

第一单位： Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. Electronic address: kwabena.asare@caprisa.org.

作者： Kwabena,Asare ^[1] ; Yukteshwar,Sookrajh ^[2] ; Johan,van der Molen ^[3] ; Thokozani,Khubone ^[2] ; Lara,Lewis ^[3] ; Richard J,Lessells ^[4] ; Kogieleum,Naidoo ^[5] ; Phelelani,Sosibo ^[2] ; Rosemary,van Heerden ^[2] ; Nigel,Garrett ^[6] ; Jienchi,Dorward ^[7]

作者单位： Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. Electronic address: kwabena.asare@caprisa.org. ^[1] eThekwini Municipality Health Unit, eThekwini Municipality, Durban, South Africa. ^[2] Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. ^[3] Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa. ^[4] Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. ^[5] Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. ^[6] Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. ^[7]

医学主题词男(雄)性(Male);女(雌)性(Female);人类(Humans);成年人(Adult);逆转录酶抑制剂(Reverse Transcriptase Inhibitors);回顾性研究(Retrospective Studies);抗HIV药(Anti-HIV Agents);HIV感染(HIV Infections);南非(South Africa);抗逆转录病毒药(Anti-Retroviral Agents);病毒载量(Viral Load);杂环化合物, 3环(Heterocyclic Compounds, 3-Ring);恶嗪类(Oxazines);哌嗪类(Piperazines);吡啶酮类(Pyridones)

DOI 10.1016/S2214-109X(23)00516-8

PMID 38142692

发布时间 2025-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The Lancet. Global health

2024年12卷2期

e282-e291页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

The Lancet. Global health

2024年12卷2期

e282-e291页

检索历史清除

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.

The Lancet. Global health

相似文献

同项目论文

The Lancet. Global health

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.

The Lancet. Global health

相似文献

同项目论文

The Lancet. Global health

相关期刊

检索历史清除